Opportunity ID: 358724
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525ALSRPTDA |
| Funding Opportunity Title: | DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Apr 18, 2025 |
| Last Updated Date: | May 23, 2025 |
| Original Closing Date for Applications: | Aug 27, 2025 |
| Current Closing Date for Applications: | Aug 27, 2025 |
| Archive Date: | Sep 26, 2025 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited Amyotrophic Lateral Sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY25 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Pages 4 and 9 of the Program Announcement (PA) have been updated to reflect a change in the funding details from a total direct cost cap to a total cost cap. The Estimated Total Program Funding amount has been updated in the PA and synopsis. Additionally, a weblink under section 6.4 has been updated in the PA (page 26). | May 23, 2025 | |
| Grantor contact info updated | Apr 18, 2025 | |
| Apr 18, 2025 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525ALSRPTDA |
| Funding Opportunity Title: | DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Apr 18, 2025 |
| Last Updated Date: | May 23, 2025 |
| Original Closing Date for Applications: | Aug 27, 2025 |
| Current Closing Date for Applications: | Aug 27, 2025 |
| Archive Date: | Sep 26, 2025 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited Amyotrophic Lateral Sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY25 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525ALSRPTDA |
| Funding Opportunity Title: | DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 18, 2025 |
| Last Updated Date: | Apr 18, 2025 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 27, 2025 |
| Archive Date: | Sep 26, 2025 |
| Estimated Total Program Funding: | $9,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited Amyotrophic Lateral Sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY25 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525ALSRPTDA |
| Funding Opportunity Title: | DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 18, 2025 |
| Last Updated Date: | Apr 18, 2025 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 27, 2025 |
| Archive Date: | Sep 26, 2025 |
| Estimated Total Program Funding: | $9,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited Amyotrophic Lateral Sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY25 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Jamie Shortall
Grant Officer Phone 301-619-2393 Email:jamie.a.shortall.civ@health.mil |
Related Documents
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00290608 | Apr 18, 2025 | Aug 27, 2025 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
